Thromboxane Prostaglandin Receptor Antagonist and Carotid Atherosclerosis Progression in Patients With Cerebrovascular Disease of Ischemic Origin | Zendy

Michiel L. Bots | Zendy; Ian Ford | Zendy; Suzanne M. Lloyd | Zendy; Stéphane Laurent | Zendy; Pierre Touboul | Zendy; Michael G. Hennerici | Zendy

Open Access

Thromboxane Prostaglandin Receptor Antagonist and Carotid Atherosclerosis Progression in Patients With Cerebrovascular Disease of Ischemic Origin

Author(s) -

Michiel L. Bots,

Ian Ford,

Suzanne M. Lloyd,

Stéphane Laurent,

Pierre Touboul,

Michael G. Hennerici

Publication year - 2014

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.114.004775

Subject(s) - medicine , thromboxane , antagonist , cardiology , receptor antagonist , stroke (engine) , disease , prostaglandin , ischemic stroke , receptor , ischemia , platelet , mechanical engineering , engineering

Thromboxane prostaglandin receptors have been implicated to be involved in the atherosclerotic process. We assessed whether Terutroban, a thromboxane prostaglandin receptor antagonist, affects the progression of atherosclerosis, as measured by common carotid intima-media thickness and carotid plaques.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research